These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 27227739)
21. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes]. Camacho Á; Rivero A Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874 [TBL] [Abstract][Full Text] [Related]
22. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. Chappell CA; Lamorde M; Nakalema S; Chen BA; Mackline H; Riddler SA; Cohn SE; Darin KM; Achilles SL; Scarsi KK AIDS; 2017 Sep; 31(14):1965-1972. PubMed ID: 28692531 [TBL] [Abstract][Full Text] [Related]
23. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). Echeverría P; Negredo E; Carosi G; Gálvez J; Gómez JL; Ocampo A; Portilla J; Prieto A; López JC; Rubio R; Mariño A; Pedrol E; Viladés C; del Arco A; Moreno A; Bravo I; López-Blazquez R; Pérez-Alvarez N; Clotet B Antiviral Res; 2010 Feb; 85(2):403-8. PubMed ID: 19941906 [TBL] [Abstract][Full Text] [Related]
24. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515 [TBL] [Abstract][Full Text] [Related]
25. Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients. Egaña-Gorroño L; Martínez E; Domingo P; Loncà M; Escribà T; Fontdevila J; Vidal F; Negredo E; Gatell JM; Arnedo M Antimicrob Agents Chemother; 2014 Nov; 58(11):6717-23. PubMed ID: 25155608 [TBL] [Abstract][Full Text] [Related]
26. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults. Gatell Artigas JM; Arribas López JR; Lázaro Y de Mercado P; Blasco Bravo AJ Enferm Infecc Microbiol Clin; 2016; 34(7):427-30. PubMed ID: 25749416 [TBL] [Abstract][Full Text] [Related]
27. Simultaneous quantitation of zidovudine, efavirenz, lopinavir and ritonavir in human hair by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Chu L; Wu Y; Duan C; Yang J; Yang H; Xie Y; Zhang Q; Qiao S; Li X; Shen Z; Deng H J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Oct; 1097-1098():54-63. PubMed ID: 30205232 [TBL] [Abstract][Full Text] [Related]
28. Does efavirenz replacement improve neurological function in treated HIV infection? Payne B; Chadwick TJ; Blamire A; Anderson KN; Parikh J; Qian J; Hynes AM; Wilkinson J; Price DA; HIV Med; 2017 Oct; 18(9):690-695. PubMed ID: 28247479 [TBL] [Abstract][Full Text] [Related]
29. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients. Cai J; Xiao J; Zhang Q Chin Med J (Engl); 2014; 127(14):2632-6. PubMed ID: 25043080 [TBL] [Abstract][Full Text] [Related]
31. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K; Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703 [TBL] [Abstract][Full Text] [Related]
32. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials. Huang X; Xu Y; Yang Q; Chen J; Zhang T; Li Z; Guo C; Chen H; Wu H; Li N Sci Rep; 2015 Feb; 5():8528. PubMed ID: 25704206 [TBL] [Abstract][Full Text] [Related]
34. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings? Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332 [TBL] [Abstract][Full Text] [Related]
35. Observational study to evaluate clinical outcomes after first-line efavirenz-or lopinavir-ritonavir-based HAART in treatment-naive patients. Pérez-Elías MJ; Moreno A; Casado JL; Dronda F; Antela A; López D; Quereda C; Navas E; Hermida JM; Del Sol E; Moreno S J Int Assoc Physicians AIDS Care (Chic); 2009; 8(5):308-13. PubMed ID: 19721095 [TBL] [Abstract][Full Text] [Related]
36. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure. Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626 [TBL] [Abstract][Full Text] [Related]
37. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. Pasipanodya B; Kuwengwa R; Prust ML; Stewart B; Chakanyuka C; Murimwa T; Brophy J; Salami O; Mushavi A; Apollo T J Int AIDS Soc; 2018 Dec; 21(12):e25214. PubMed ID: 30549217 [TBL] [Abstract][Full Text] [Related]